These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1101 related articles for article (PubMed ID: 15207766)
21. Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Hofbauer LC; Shui C; Riggs BL; Dunstan CR; Spelsberg TC; O'Brien T; Khosla S Biochem Biophys Res Commun; 2001 Jan; 280(1):334-9. PubMed ID: 11162519 [TBL] [Abstract][Full Text] [Related]
23. Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells. Humphrey EL; Williams JH; Davie MW; Marshall MJ Bone; 2006 May; 38(5):652-61. PubMed ID: 16298558 [TBL] [Abstract][Full Text] [Related]
24. Bone stromal cells in pagetic bone and Paget's sarcoma express RANKL and support human osteoclast formation. Sun SG; Lau YS; Itonaga I; Sabokbar A; Athanasou NA J Pathol; 2006 May; 209(1):114-20. PubMed ID: 16482498 [TBL] [Abstract][Full Text] [Related]
25. Receptor activator NFkappaB-ligand and osteoprotegerin protein expression in human periapical cysts and granulomas. Menezes R; Bramante CM; da Silva Paiva KB; Letra A; Carneiro E; Fernando Zambuzzi W; Granjeiro JM Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Sep; 102(3):404-9. PubMed ID: 16920551 [TBL] [Abstract][Full Text] [Related]
26. Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and cathepsin K. Mandelin J; Li TF; Hukkanen M; Liljeström M; Salo J; Santavirta S; Konttinen YT J Rheumatol; 2005 Apr; 32(4):713-20. PubMed ID: 15801030 [TBL] [Abstract][Full Text] [Related]
27. Long wave ultrasound may enhance bone regeneration by altering OPG/RANKL ratio in human osteoblast-like cells. Maddi A; Hai H; Ong ST; Sharp L; Harris M; Meghji S Bone; 2006 Aug; 39(2):283-8. PubMed ID: 16567138 [TBL] [Abstract][Full Text] [Related]
28. Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland. Hofbauer LC; Kluger S; Kühne CA; Dunstan CR; Burchert A; Schoppet M; Zielke A; Heufelder AE J Cell Biochem; 2002; 86(4):642-50. PubMed ID: 12210731 [TBL] [Abstract][Full Text] [Related]
29. Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis. Lu HK; Chen YL; Chang HC; Li CL; Kuo MY J Periodontal Res; 2006 Aug; 41(4):354-60. PubMed ID: 16827732 [TBL] [Abstract][Full Text] [Related]
30. Effects of polyethylene and TiAlV wear particles on expression of RANK, RANKL and OPG mRNA. Baumann B; Rader CP; Seufert J; Nöth U; Rolf O; Eulert J; Jakob F Acta Orthop Scand; 2004 Jun; 75(3):295-302. PubMed ID: 15260421 [TBL] [Abstract][Full Text] [Related]
31. IL-6 is not required for parathyroid hormone stimulation of RANKL expression, osteoclast formation, and bone loss in mice. O'Brien CA; Jilka RL; Fu Q; Stewart S; Weinstein RS; Manolagas SC Am J Physiol Endocrinol Metab; 2005 Nov; 289(5):E784-93. PubMed ID: 15956054 [TBL] [Abstract][Full Text] [Related]
32. Osteoprotegerin is expressed in colon carcinoma cells. Pettersen I; Bakkelund W; Smedsrød B; Sveinbjørnsson B Anticancer Res; 2005; 25(6B):3809-16. PubMed ID: 16309167 [TBL] [Abstract][Full Text] [Related]
33. Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium. Atkins GJ; Kostakis P; Welldon KJ; Vincent C; Findlay DM; Zannettino AC J Cell Physiol; 2005 Jun; 203(3):573-82. PubMed ID: 15573398 [TBL] [Abstract][Full Text] [Related]
34. Expression of RANKL and OPG in middle ear cholesteatoma tissue. Jeong JH; Park CW; Tae K; Lee SH; Shin DH; Kim KR; Park YW Laryngoscope; 2006 Jul; 116(7):1180-4. PubMed ID: 16826057 [TBL] [Abstract][Full Text] [Related]
35. Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins. Abrahamsen B; Hjelmborg JV; Kostenuik P; Stilgren LS; Kyvik K; Adamu S; Brixen K; Langdahl BL Bone; 2005 Apr; 36(4):727-35. PubMed ID: 15781001 [TBL] [Abstract][Full Text] [Related]
36. Osteosclerosis in advanced chronic idiopathic myelofibrosis is associated with endothelial overexpression of osteoprotegerin. Bock O; Loch G; Schade U; Büsche G; Wasielewski R; Wiese B; Kreipe H Br J Haematol; 2005 Jul; 130(1):76-82. PubMed ID: 15982347 [TBL] [Abstract][Full Text] [Related]
37. Osteoprotegerin levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. Stilgren LS; Hegedüs LM; Beck-Nielsen H; Abrahamsen B Calcif Tissue Int; 2003 Sep; 73(3):210-6. PubMed ID: 14667132 [TBL] [Abstract][Full Text] [Related]
38. Atorvastatin stimulates the production of osteoprotegerin by human osteoblasts. Viereck V; Gründker C; Blaschke S; Frosch KH; Schoppet M; Emons G; Hofbauer LC J Cell Biochem; 2005 Dec; 96(6):1244-53. PubMed ID: 16152630 [TBL] [Abstract][Full Text] [Related]
39. [Ascorbic acid inhibits the formation and function of osteoclasts from RAW264.7 cells induced by receptor activated nuclear factor kappaB ligand in vitro]. Xiao XH; Zhou HD; Yuan LQ; Xie H; Liao EY Zhonghua Yi Xue Za Zhi; 2004 Dec; 84(24):2102-6. PubMed ID: 15730627 [TBL] [Abstract][Full Text] [Related]
40. Targeted overexpression of G protein-coupled receptor kinase-2 in osteoblasts promotes bone loss. Wang L; Liu S; Quarles LD; Spurney RF Am J Physiol Endocrinol Metab; 2005 Apr; 288(4):E826-34. PubMed ID: 15585587 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]